Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors

Angiogenesis

Volumn 16, Issue 1, 2013, Pages 159-170

  Koskimaki, Jacob E ^a   Lee, Esak ^b   Chen, William ^a   Rivera, Corban G ^a   Rosca, Elena V ^a   Pandey, Niranjan B ^a   Popel, Aleksander S ^a,b,c  

^a Johns Hopkins University   (United States)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Combination therapy; Inhibitor; Peptide; Synergy

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA1 INTEGRIN; COLLAGEN TYPE 4; FOCAL ADHESION KINASE; GROWTH HORMONE; LYMPHANGIOGENESIS INHIBITOR; PEPTIDE SP2000; PEPTIDE SP2012; PEPTIDE SP5001; PEPTIDE SP5031; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CAPILLARY TUBE; CELL ADHESION; CELL MIGRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONTENT; RETINA MACULA AGE RELATED DEGENERATION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; CELL ADHESION; CELL MOVEMENT; COLLAGEN TYPE IV; DRUG SYNERGISM; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FOCAL ADHESION KINASE 1; GROWTH HORMONE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84871611863     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9308-7     Document Type: Article

References (34)

1. Potente M, Gerhardt H, Carmeliet P (2011) Basic and therapeutic aspects of angiogenesis. Cell 146(6):873-887. doi: 10.1016/j.cell.2011.08.039
2. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417-427. doi: 10.1038/nrd3455
3. Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R (2011) Forty-year journey of angiogenesis translational research. Sci Transl Med 3(114):114rv113. doi: 10.1126/scitranslmed.3003149
4. Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8(4):210-221. doi: 10.1038/nrclinonc.2011.21
5. Kerbel RS (2009) Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 18(Suppl 3):S41-S47. doi: 10.1016/S0960-9776(09)70271-1
6. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307. doi: 10.1038/nature10144
7. Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15(3):167-170. doi: 10.1016/j.ccr.2009.02.007
8. Albrecht I, Christofori G (2011) Molecular mechanisms of lymphangiogenesis in development and cancer. Int J Dev Biol 55(4-5):483-494. doi: 10.1387/ijdb.103226ia
9. Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, Swartz MA (2012) VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 1(3):191-199. doi: 10.1016/j.celrep.2012.01.005
10. Karagiannis ED, Popel AS (2008) A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA 105(37):13775-13780. doi: 10.1073/pnas.0803241105
11. Karagiannis ED, Popel AS (2007) Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun 354(2):434-439. doi: 10.1016/j.bbrc.2006.12.231
12. Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT Jr, Raman V, Bhujwalla ZM, Popel AS (2009) Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia 11(12):1285-1291
13. Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS (2010) Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer 10:29. doi: 10.1186/1471-2407-10-29
14. Rosca EV, Lal B, Koskimaki JE, Popel AS, Laterra J (2012) Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth. Anticancer Drugs. doi: 10.1097/CAD.0b013e3283531041
15. Rosca EV, Koskimaki JE, Pandey NB, Wolff AC, Popel AS (2011) Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther 12(9):808-817
16. Rivera CG, Rosca EV, Pandey NB, Koskimaki JE, Bader JS, Popel AS (2011) Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J Med Chem 54(19):6492-6500. doi: 10.1021/jm200114f
17. Rosca EV, Koskimaki JE, Pandey NB, Tamiz AP, Popel AS (2012) Structure-activity relationship study of collagen derived anti-angiogenic biomimetic peptides. Chem Biol Drug Des. doi: 10.1111/j.1747-0285.2012.01376.x
18. Lee E, Rosca EV, Pandey NB, Popel AS (2011) Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol 43(12):1812-1821. doi: 10.1016/j.biocel.2011.08.020
19. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE, Abdollahi A (2005) Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65(9):3643-3655. doi: 10.1158/0008-5472.CAN-04-1668
20. Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001
21. Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS (2011) Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 12(8):1101-1116
22. Saladin PM, Zhang BD, Reichert JM (2009) Current trends in the clinical development of peptide therapeutics. IDrugs 12(12):779-784
23. Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT (2011) Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem 286(15):13626-13637. doi: 10.1074/jbc.M110.216820
24. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
25. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440-446. doi: 10.1158/0008-5472.CAN-09-1947
26. Rosca EV, Koskimaki JE, Pandey NB, Wolff AC, Popel AS (2011) Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther 12(9):808-817. doi: 10.4161/cbt.12.9.17677
27. Zhang Z, Vuori K, Reed JC, Ruoslahti E (1995) The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92(13):6161-6165
28. Le Boeuf F, Houle F, Huot J (2004) Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 279(37):39175-39185. doi: 10.1074/jbc.M405493200
29. Zhao X, Guan JL (2011) Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 63(8):610-615. doi: 10.1016/j.addr.2010.11.001
30. Infusino GA, Jacobson JR (2011) Endothelial FAK as a therapeutic target in disease. Microvasc Res. doi: 10.1016/j.mvr.2011.09.011
31. Xiong Y, Huo Y, Chen C, Zeng H, Lu X, Wei C, Ruan C, Zhang X, Hu Z, Shibuya M, Luo J (2009) Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathways. J Biol Chem 284(35):23217-23224. doi: 10.1074/jbc.M109.019679
32. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21(16):2555-2563. doi: 10.1038/sj.onc.1205332
33. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD (2009) FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 12(3):81-89. doi: 10.1016/j.drup.2009.04.001
34. Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE (2008) Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 28(10):1703-1713. doi: 10.1161/ATVBAHA.108.172015